Potential cardiovascular effects of incretin-based therapies

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 3, 2012, Pages 337-351

  Deacon, Carolyn F ^a   Marx, Nikolaus ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

arteriosclerosis; cardiovascular risk; dipeptidyl peptidase 4; DPP 4 inhibitor; endothelial function; GLP 1 agonist; glucagon like peptide 1; incretin

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; DULAGLUTIDE; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LINAGLIPTIN; LIPID; LIRAGLUTIDE; LIXISENATIDE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL INJURY; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONTINUOUS INFUSION; EXPERIMENTAL DOG; HEART INFARCTION SIZE; HEART PERFORMANCE; HEART PROTECTION; HEART RATE; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT CARE; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; RISK FACTORS;

EID: 84858198995     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.5     Document Type: Review

References (136)

1. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in Type II diabetic patients and in healthy subjects. Diabetes 44, 1126-1131 (1995).
2. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 diabetes. Diabetes 47, 1663-1670 (1998). (Pubitemid 28476238)
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234 (1998). (Pubitemid 28350165)
4. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 358, 219-224 (1995).
5. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137, 2968-2978 (1996). (Pubitemid 26192194)
6. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2007). (Pubitemid 46711096)
7. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117, 2340-2350 (2008). (Pubitemid 351653542)
8. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia-reperfusion injury. Diabetes 54, 146-151 (2005). (Pubitemid 40105106)
9. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc. Drugs Ther. 21, 253-256 (2007). (Pubitemid 47387464)
10. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 61, 448-460 (2004). (Pubitemid 38210151)
11. Nyström T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287, e1209-e1215 (2004). (Pubitemid 39491964)
12. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133, 2861-2870 (1993). (Pubitemid 24000747)
13. Zhong Q, Bollag RJ, Dransfield DT et al. Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells. Peptides 21, 1427-1432 (2000).
14. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia-reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc. Drugs Ther. 19, 9-11 (2005). (Pubitemid 40767767)
15. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept. 146, 243-249 (2008).
16. Noyan-Ashraf MH, Momen MA, Ban K et al. The GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Diabetes 58, 975-983 (2009).
17. Bao W, Aravindhan K, Alsaid H et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia-reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 6, e23570 (2010).
18. Sauvé M, Ban K, Momen MA et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59, 1063-1073 (2010).
19. Hausenloy DJ, Wynne AM, Theodorou L, Mocanu MM, Yellon DM. Dipeptidyl peptidase IV inhibitors limit myocardial infarct size in a glucose-sensitive manner. Heart 96, e11 (2010) (Abstract FC1).
20. Zhao T, Parikh P, Bhashyam S et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317, 1106-1113 (2006). (Pubitemid 43764114)
21. Ravassa S, Zudaire A, Carr RD, Díez J. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 300, H1361-H1372 (2011).
22. Lenski M, Kazakov A, Marx N, Böhm M, Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J. Mol. Cell Cardiol. 51, 906-918 (2011).
23. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am. J. Physiol. Endocrinol. Metab. 279, E1104-E1113 (2000).
24. Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm. Metab. Res. 43, 300-305 (2011).
25. Ban K, Kim KH, Cho CK et al. Glucagon-like peptide (GLP)-1(9-36) amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151, 1520-1531 (2010).
26. Nikolaidis LA, Doverspike A, Hentosz T et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J. Pharmacol. Exp. Ther. 312, 303-308 (2005). (Pubitemid 40096482)
27. Kavianipour M, Ehlers MR, Malmberg K et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 24, 569-578 (2003). (Pubitemid 36829346)
28. Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc. Disord. 9, 31 (2009).
29. Timmers L, Henriques JP, de Kleijn DP et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53, 501-510 (2009).
30. Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109, 962-965 (2004). (Pubitemid 38282847)
31. Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart doi:10.1136/ hrt.2010.219345 (2011) (Epub ahead of print).
32. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ. Cardiovasc. Imaging 3, 195-201 (2010).
33. Read PA, Hoole SP, White PA et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv. 4, 266-272 (2011).
34. Sokos GG, Bolukoglu H, German J et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol. 100, 824-829 (2007). (Pubitemid 47268274)
35. Müssig K, Oncü A, Lindauer P et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with Type 2 diabetes. Am. J. Cardiol. 102, 646-647 (2008).
36. Lønborg J, Vejlstrup N, Kelbaek H et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. doi:10.1093/eurheartj/ehr309 (2011) (Epub ahead of print).
37. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ. Heart Fail. 1, 153-160 (2008).
38. Vyas AK, Yang KC, Woo D et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 6, e17178 (2011).
39. Liu Q, Anderson C, Broyde A et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc. Diabetol. 9, 76 (2010).
40. Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110, 955-961 (2004). (Pubitemid 39128621)
41. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289, H2401-H2408 (2005). (Pubitemid 41698549)
42. Bhashyam S, Fields AV, Patterson B et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ. Heart Fail. 3, 512-521 (2010).
43. Gomez N, Touihri K, Matheeussen V et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur. J. Heart Fail. 14, 14-21 (2012).
44. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 12, 694-699 (2006). (Pubitemid 44881367)
45. Halbirk M, Nørrelund H, Møller N et al. Cardiovascular and metabolic effects of 48 h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am. J. Physiol. Heart Circ. Physiol. 298, H1096-H1102 (2010).
46. Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept. 125, 173-177 (2005). (Pubitemid 39593722)
47. Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nyström T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul. Pept. 157, 8-13 (2009).
48. Gaspari T, Liu H, Welungoda I et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab. Vasc. Dis. Res. 8, 117-124 (2011).
49. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28, 812-819 (2008). (Pubitemid 351544093)
50. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ. J. 73, 595-601 (2009).
51. Arakawa M, Mita T, Azuma K et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59, 1030-1037 (2010).
52. Goto H, Nomiyama T, Mita T et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem. Biophys. Res. Commun. 405, 79-84 (2011).
53. Murthy SN, Hilaire RC, Casey DB et al. The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats. Diab. Vasc. Dis. Res. 7, 138-144 (2010).
54. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem. Biophys. Res. Commun. 391, 1405-1408 (2010).
55. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol. 201, 59-66 (2009).
56. Hattori Y, Jojima T, Tomizawa A et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53, 2256-2263 (2010).
57. Nagashima M, Watanabe T, Terasaki M et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54, 2649-2659 (2011).
58. Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. 58, 157-166 (2011).
59. Shah Z, Kampfrath T, Deiuliis JA et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124, 2338-2349 (2011).
60. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab. 293, E1289-E1295 (2007). (Pubitemid 350106596)
61. Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an endothelial resistance' to glucagon-like peptide 1 in diabetes. Diabetes Care 34, 697-702 (2011).
62. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset Type 2 diabetes. Diabetes Care 33, 1028-1030 (2010).
63. Lundkvist J, Berne C, Bolinder B, Jönsson L. The economic and quality of life impact of hypoglycemia. Eur. J. Health Econ. 6, 197-202 (2005). (Pubitemid 41638842)
64. Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with Type 1 and Type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 26, 1153-1157 (2003). (Pubitemid 36929264)
65. Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr. Pract. 14, 750-756 (2008).
66. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33, 1389-1394 (2010).
67. Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in Type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340, b4909 (2010).
68. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 123, 342-348 (2011).
69. Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with Type 2 diabetes. Diabetes Care 34, 1164-1170 (2011).
70. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr. Opin. Clin. Nutr. Metab. Care 11, 491-499 (2008).
71. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in Type 2 diabetes. JAMA 303, 1410-1418 (2010).
72. Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. Curr. Hypertens. Rep. 13, 452-455 (2011).
73. Barragán JM, Rodríguez RE, Blázquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am. J. Physiol. 266, E459-E466 (1994).
74. Barragán JM, Rodríguez RE, Eng J, Blázquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul. Pept. 67, 63-68 (1996). (Pubitemid 26384196)
75. Yu M, Moreno C, Hoagland KM et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens. 21, 1125-1135 (2003). (Pubitemid 36667866)
76. Hirata K, Kume S, Araki S et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem. Biophys. Res. Commun. 380, 44-49 (2009).
77. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with Type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 33, 1759-1765 (2010).
78. Mistry GC, Maes AL, Lasseter KC et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J. Clin. Pharmacol. 48, 592-598 (2008). (Pubitemid 351503521)
79. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with Type 2 diabetes. Am. J. Hypertens. 23, 334-339 (2010).
80. Gill A, Hoogwerf BJ, Burger J et al. Effect of exenatide on heart rate and blood pressure in subjects with Type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc. Diabetol. 9, 6 (2010).
81. Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int. J. Clin. Pract. 64, 267-276 (2009).
82. Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with Type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375, 1447-1456 (2010).
83. Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann. Pharmacother. 45, 850-860 (2011).
84. Edwards CM, Edwards AV, Bloom SR. Cardiovascular and pancreatic endocrine responses to glucagon-like peptide-1(7-36) amide in the conscious calf. Exp. Physiol. 82, 709-716 (1997). (Pubitemid 27363855)
85. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39-47 (2009).
86. Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 96, 1301-1310 (2011).
87. Griffioen KJ, Wan R, Okun E et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc. Res. 89, 72-78 (2011).
88. Gustavson SM, Chen D, Somayaji V et al. Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. 13, 1056-1058 (2011).
89. Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J. Am. Coll. Cardiol. 50, 823-830 (2007). (Pubitemid 47277500)
90. Verdich C, Flint A, Gutzwiller JP et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 86, 4382-4389 (2001).
91. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in Type 2 diabetes: a parallel-group study. Lancet 359, 824-830 (2002). (Pubitemid 34233752)
92. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152, 3103-3112 (2011).
93. Orskov C, Poulsen SS, Møller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45, 832-935 (1996).
94. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27, 1915-1921 (2004). (Pubitemid 38989232)
95. Jendle J, Nauck MA, Matthews DR et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for Type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes. Metab. 11, 1163-1172 (2009).
96. Bunck MC, Diamant M, Eliasson B et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33, 1734-1737 (2010).
97. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275-286 (2008). (Pubitemid 351160260)
98. Edwards CM, Stanley SA, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab. 281, E155-E161 (2001).
99. Pinelli NR, Jantz A, Smith Z et al. Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers. J. Clin. Pharmacol. 51, 165-172 (2011).
100. Sze L, Purtell L, Jenkins A et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 96, E1314-E1319 (2011).
101. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet 373, 473-481 (2009).
102. Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol. Med. 14, 161-168 (2008).
103. Esposito K, Cozzolino D, Bellastella G et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of
104. Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc. Diabetol. 10, 61 (2011).
105. Meier JJ, Gethmann A, Götze O et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49, 452-458 (2006). (Pubitemid 43277867)
106. Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with Type 2 diabetes. Diabetologia 49, 2049-2057 (2006). (Pubitemid 44168471)
107. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset Type 2 diabetes mellitus. Atherosclerosis 212, 217-222 (2010).
108. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with Type 2 diabetes. Diabetes Obes. Metab. 13, 366-373 (2011).
109. Hsieh J, Longuet C, Baker CL et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53, 552-561 (2010).
110. Derosa G, Maffioli P, Salvadeo SA et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled Type 2 diabetes mellitus patients. Metabolism 59, 887-895 (2010).
111. Derosa G, Maffioli P, Ferrari I et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled Type 2 diabetic patients. Horm. Metab. Res. 42, 663-669 (2010).
112. Courrèges JP, Vilsbøll T, Zdravkovic M et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med. 25, 1129-1131 (2008).
113. Bethel MA, Green J, Califf RM, Holman RR. Rationale and design of the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes 58(Suppl. 1), A555 (2009) (Abstract 2152- PO).
114. White WB, Bakris GL, Bergenstal RM et al. Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with Type 2 diabetes with acute coronary syndrome. Am. Heart J. 162, 620-626.e1 (2011).
115. Scirica BM, Bhatt DL, Braunwald E et al. The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. Am. Heart J. 162(5), 818-825.e6 (2011).
116. Rosenstock J, Marx N, Kahn SE et al. The rationale and design of the CAROLINA trial: an Active Comparator Cardiovascular Outcome Study of the DPP-4 Inhibitor Linagliptin in Patients with Type 2 Diabetes at High Cardiovascular Risk. Diabetes 60(Suppl. 1), A303 (2011) (Abstract 1103-P).
117. Williams-Herman D, Engel SS, Round E et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with Type 2 diabetes. BMC. Endocr. Disord. 10, 7 (2010).
118. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III Type 2 diabetes population. Diabetes Obes. Metab. 12, 485-494 (2010).
119. White WB, Gorelick PB, Fleck P, Smith N, Wilson C, Pratley R. Cardiovascular events in patients receiving alogliptin: a pooled analysis of randomized clinical trials. Diabetes 59(Suppl. 1), A105 (2010) (Abstract 391-PP).
120. Frederich R, Alexander JH, Fiedorek FT et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for Type 2 diabetes. Postgrad. Med. 122, 16-27 (2010).
121. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with Type 2 diabetes. Cardiovasc. Diabetol. 10, 22 (2011).
122. Marso SP, Lindsey JB, Stolker JM et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of Phase 2: 3 liraglutide clinical development studies. Diab. Vasc. Dis. Res. 8, 237-240 (2011).
123. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with Type 2 diabetes mellitus: a prespecified, prospective, and adjudicated meta-analysis of a Phase 3 programme. Cardiovasc. Diabetol. 11, 3 (2012).
124. Monami M, Cremasco F, Lamanna C et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp. Diabetes Res. 2011, 215764 (2011).
125. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr. Med. Res. Opin. 27, 57-64 (2011).
126. Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients withType 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34, 90-95 (2011).
127. Best JH, Little W, Chiquette E, Saunders WB. The risk of heart failure among patients receiving exenatide versus other glucose-lowering medications for Type 2 diabetes: a matched retrospective cohort analysis of the GE healthcare electronic medical record database. Diabetes 60(Suppl. 1), A311 (2011) (Abstract 1133-P).
128. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med. 353, 2643-5326 (2005).
129. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008). (Pubitemid 351831356)
130. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008). (Pubitemid 351831357)
131. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med. 360, 129-139 (2009).
132. Treiman M, Elvekjaer M, Engstrøm T, Jensen JS. Glucagon-like peptide 1 - a cardiologic dimension. Trends Cardiovasc. Med. 20, 8-12 (2010).
133. Fadini GP, Boscaro E, Albiero M et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with Type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33, 1607-1609 (2010).
134. Kanki S, Segers VF, Wu W et al. Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium. Circ. Heart Fail. 4, 509-518 (2011).
135. Scholte M, Timmers L, Bernink FJ et al. Effect of additional treatment with exenatide in patients with an acute myocardial infarction (EXAMI): study protocol for a randomized controlled trial. Trials 12, 240 (2011).
136. Hausenloy DJ, Yellon DM. Taking lizard saliva to heart. Eur. Heart J. doi:10.1093/ eurheartj/ehr382 (2011) (Epub ahead of print).